December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eagle Pharmaceuticals, Inc. - Common Stock (NQ:EGRX)

2.140 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eagle Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Recap: Eagle Pharmaceuticals Q3 Earnings
Eagle Pharmaceuticals (NASDAQ:EGRX) reported its Q3 earnings results on Monday, November 7, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose
 
Via Benzinga
Eagle Pharma Broadens Acute Care Portfolio With Equity Stake In Respiratory Depression Player
 
Via Benzinga
Recap: Eagle Pharmaceuticals Q1 Earnings
Eagle Pharmaceuticals (NASDAQ:EGRX) reported its Q1 earnings results on Monday, May 9, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday, 52 stocks hit new 52-week lows. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eagle Pharmaceuticals: Q2 Earnings Insights
  Eagle Pharmaceuticals (NASDAQ:EGRX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:50 AM. Here's what investors need to know about the announcement. Earnings Eagle Pharmaceuticals... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 61 companies made new 52-week lows. 
Via Benzinga
Perrigo Stock Mystery; Big Money Loves It, Though Profits Slim
Institutional investors like mutual funds can't get enough of Perrigo stock. It has an A Accumulation/Distribution Rating. 
Via Investor's Business Daily
Short Volatility Alert: Eagle Pharmaceuticals, Inc.
On Tuesday, shares of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) experienced volatile short activity. After the activity, the stock price went up +2.39% to $43.35. The overall sentiment for EGRX has... 
Via Benzinga
Eagle Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know
Eagle Pharmaceuticals (NASDAQ:EGRX) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Eagle Pharma Adds Hospital-Based Products With €95M Acacia Pharma Deal
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has agreed to acquire Acacia Pharma Group plc  
Via Benzinga
Eagle Pharma's Q4 Earnings Miss Street View On Lower Product Sales
Eagle Pharmaceuticals Inc's (NASDAQ: EGRX) Q4 FY21 sales declined 15% Y/Y to $42.3 million, missing the consensus of $51.08 million. The sales declined primarily... 
Via Benzinga
Eagle Pharmaceuticals: Q4 Earnings Insights
Eagle Pharmaceuticals (NASDAQ:EGRX) reported its Q4 earnings results on Monday, March 7, 2022 at 06:50 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 7, 2022
Companies Reporting Before The Bell • Niu Technologies (NASDAQ:NIU) is expected to report quarterly earnings at $0.21 per share on revenue of $144.02 million. •... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Eagle Pharmaceuticals's Earnings Outlook
Eagle Pharmaceuticals (NASDAQ:EGRX) is set to give its latest quarterly earnings report on Monday, 2022-03-07. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.